FAM20C

If you or a family member has been told a child has unexplained bone hardening, brain calcifications, dental abnormalities, or stubbornly low blood phosphate, this is the gene worth knowing about. FAM20C (Family With Sequence Similarity 20 Member C) sequencing can identify a rare inherited cause of these problems, and it is increasingly used for couples planning a pregnancy when there is a family history of unusual skeletal disease.

This is a research-grade and specialty test rather than a routine wellness marker. It is most useful when there is a clinical reason to suspect a rare bone-mineral disease called Raine syndrome, when a family is doing reproductive carrier screening, or when standard workups for low phosphate have come back empty.

What This Gene Actually Does

FAM20C carries the instructions for a protein-modifying enzyme (a kinase, which attaches phosphate tags onto other proteins) that sits inside a cell compartment called the Golgi, which is where cells finish and package proteins before sending them out. This enzyme adds phosphate tags to more than 100 different proteins that your body secretes, generating the majority of what scientists call the secreted phosphoproteome (the collection of secreted proteins carrying these phosphate tags).

Most of the proteins it tags are involved in building hard tissues. It works heavily in bone, dentin (the layer under your enamel), and tooth enamel, where it activates a family of mineralization proteins including DMP1, MEPE, osteopontin, bone sialoprotein, and dentin sialophosphoprotein. It also adds tags to FGF23 (fibroblast growth factor 23), the hormone that tells your kidneys how much phosphate to keep versus dump in the urine.

When the gene works normally, your skeleton and teeth mineralize properly and your blood phosphate stays in range. When both copies of the gene are broken, the chain of tagging falls apart, and the downstream effects show up across bone, teeth, brain, and kidney.

Raine Syndrome

The clearest disease connection is Raine syndrome, a rare condition caused when both copies of FAM20C carry loss-of-function changes. It exists on a spectrum. The severe form is a lethal newborn disease with widespread bone hardening (osteosclerosis), facial dysmorphism, and brain calcifications. Milder, non-lethal forms can present later in childhood or even in adulthood, with bone softening (osteomalacia), low blood phosphate, excessive phosphate loss in urine, and dental anomalies.

The underlying problem is consistent across the spectrum. Without working FAM20C, the mineralization proteins do not get their phosphate tags, FGF23 processing is disrupted, intact FGF23 rises in the blood, and the kidneys waste phosphate. This combination produces the hallmark picture of high FGF23, low blood phosphate, and abnormal bone.

One published cohort followed 12 children with non-lethal Raine syndrome and described diverse courses: respiratory distress in infancy, neurodevelopmental delays, and hypophosphatemic rickets that responded poorly to standard phosphate and alfacalcidol therapy. A separate case described an elderly man with mild Raine syndrome, hypophosphatemic osteomalacia, high bone mass, and spontaneous knee osteonecrosis, showing that the gene can also drive late-onset bone disease.

Hypophosphatemia Without Classic Rickets

FAM20C variants have been found in people whose main problem is unexplained low blood phosphate without the classic rickets picture. In one report, two patients with compound heterozygous FAM20C mutations had elevated intact FGF23, low phosphate, high urine phosphate, dental demineralization, bone hardening, and brain calcifications.

In a population-based study of 68 Norwegians with hereditary hypophosphatemia, FAM20C variants were found, but they were much less common than variants in PHEX, the gene responsible for X-linked hypophosphatemia (the most frequent inherited cause). If your hypophosphatemia workup has been negative for the common causes, FAM20C is one of the rarer genes worth checking.

Cancer Associations

FAM20C is not just a bone gene. A pan-cancer analysis found that high FAM20C expression in tumor tissue is associated with worse prognosis in several cancers, including bladder cancer, lower-grade glioma, and stomach adenocarcinoma. Higher expression also correlated with more immune cell infiltration of the tumor, including macrophages, neutrophils, and dendritic cells.

A separate genome-wide association study of 4,816 adults with diffuse glioma identified a risk variant near FAM20C specifically in the IDH-mutant, 1p/19q-codeleted, TERT-mutant subtype of glioma. These findings are based on tumor tissue expression and germline variants in disease cohorts, not on a blood test of FAM20C in healthy adults. They do not yet translate into a screening use case for the general population.

Reconciling the Bone and Cancer Findings

You may notice an apparent contradiction. Loss of FAM20C causes severe bone and mineral disease, yet high FAM20C expression in tumors looks bad too. This is not a paradox once you frame the gene correctly. FAM20C is not a number where higher is uniformly better or worse. It is a workhorse enzyme whose effects depend on the tissue and the substrates it acts on. In bone and tooth, you need enough activity to mineralize properly. In tumors, overactivity appears to add tags to proteins that help cancer cells migrate, invade, and shape their immune environment. Different contexts, different consequences.

Reproductive Carrier Screening

FAM20C-related Raine syndrome is inherited in an autosomal recessive pattern, meaning a child has to inherit a broken copy from each parent to develop the disease. Carriers (people with only one broken copy) are typically healthy. This is why carrier testing matters for couples with a family history of severe skeletal disease in a child, or for consanguineous couples (those who are biologically related, such as cousins), where the chance of both partners carrying the same rare recessive variant is higher than in the general population.

One important technical point: a published preconception screening study of consanguineous couples used a 4,813-gene clinical exome panel and missed a known disease-causing FAM20C single-exon deletion that had already caused Raine syndrome in a prior pregnancy. The panel-based method could not detect that type of structural variant. Whole-genome sequencing with copy-number variant analysis was recommended as the more thorough approach.

What An Out-of-Pattern Result Should Trigger

Genetic testing for FAM20C produces a different kind of result than a blood biomarker. You learn whether you carry variants in the gene, and if so, whether they are likely benign, of uncertain significance, or pathogenic. There is no "trend" to track over time, but the result still demands a decision pathway.

• If a pathogenic biallelic variant is found alongside symptoms suggestive of Raine syndrome: confirm with measurements of serum phosphate, intact FGF23, alkaline phosphatase, calcium, vitamin D metabolites, and dental and skeletal imaging. A metabolic bone specialist or pediatric endocrinologist should coordinate care.
• If a pathogenic carrier variant is found and you are planning a pregnancy: your partner should be tested for FAM20C variants. If both are carriers, a genetic counselor can discuss prenatal options including reproductive technology with preimplantation testing.
• If a variant of uncertain significance is found: do not act on it as if it were pathogenic. Ask whether segregation analysis in family members or functional testing can clarify the result.
• If you have unexplained low blood phosphate or osteomalacia: ensure the common causes (PHEX-related X-linked hypophosphatemia, tumor-induced osteomalacia, nutritional deficiencies) have been ruled out before assuming FAM20C is the answer. FAM20C variants are rare compared with PHEX.

Why One Test Is The Whole Story

Unlike blood markers, your germline DNA does not change over time. A single accurate FAM20C sequencing result is generally definitive and does not need to be repeated, as long as the testing method is thorough enough to detect the relevant variant types (sequence variants and structural variants such as exon deletions). The catch is testing method coverage. If the original test was a panel that did not look for copy-number changes, and clinical suspicion remains high, re-testing with whole-exome or whole-genome sequencing with copy-number analysis is a reasonable next step.

For the downstream biology FAM20C influences (phosphate, FGF23, bone turnover, dental health), serial monitoring of those companion labs and clinical assessments does matter, especially during growth, pregnancy, or treatment. The gene result tells you the cause. The downstream labs tell you how the disease is behaving and whether interventions are helping.

When Results Can Be Misleading

• Method limitations: Standard exome and gene-panel tests can miss single-exon deletions and other structural variants in FAM20C. A negative panel result does not rule out the gene as a cause if clinical suspicion is high.
• Variant interpretation drift: A variant called "uncertain significance" today may be reclassified as benign or pathogenic later as more data accumulates. If your result is uncertain and the clinical picture is suggestive, ask for periodic reinterpretation.
• Confusion with related genes: FAM20A is a closely related gene whose protein partners with FAM20C. FAM20A mutations cause enamel renal syndrome, a different condition with overlapping dental features. Make sure the right gene was tested and the result is interpreted in context.
• Healthy carrier status: Finding one pathogenic FAM20C variant in an adult without symptoms typically means carrier status, not active disease. This is relevant for family planning, not for personal disease risk.